Gelonghui, March 22丨Tong Ren Tang Technology (01666.HK) announced that for the year ended December 31, 2023, the Group's revenue was RMB 6.773 billion, up 13.04% year on year; net profit attributable to company owners was RMB 590 million, up 1.25% over the same period last year; earnings per share was RMB 0.46 (2022: RMB 0.46); and dividend per share was RMB 0.18 (2022: RMB 0.16).
Throughout the year, the Group is committed to adapting to the new normal in the traditional Chinese medicine industry, continuing to focus on core competitive advantages, promoting large-scale strategies, and building diversified marketing development models, while focusing on improving overall collaborative efficiency. During the reporting period, the Group continued to focus on Tongrentang's “brand, variety and quality” core competitive advantage, grasp market trends, respond positively to the continuous changes in market demand for products, adhere to the work policy of “deepening, coordination, linkage and development”, move forward cohesively and courageously, comprehensively promote innovative management, and strive to complete various tasks and targets throughout the year, taking a firm step towards the Group's completion of the “14th Five-Year Plan”.
In the new year, the Group will continue to rely on the “Tong Ren Tang” century-old brand, take the inheritors of traditional Chinese medicine culture as its mission, promote the “responsibility, responsibility and creativity” spirit of Tongrentang people in the new era, gather product synergy, market synergy, production and marketing efforts, enhance marketing efficiency, production efficiency and management efficiency, achieve the Group's high-quality development, and ensure the successful completion of the “14th Five-Year Plan” goals and tasks.